Press Release
news head

July 24, 2018

NUCLEIX ANNOUNCES PUBLICATION OF NON-INVASIVE BLADDER CANCER RECURRENCE DETECTION STUDY SHOWING BEST-IN-CLASS PERFORMANCE

read more >

Article
news head

July 1, 2018

PERFORMANCE OF THE BLADDER EPICHECK™ METHYLATION TEST FOR PATIENTS UNDER SURVEILLANCE FOR NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS OF A MULTICENTER, PROSPECTIVE, BLINDED CLINICAL TRIAL

read more >

Article
news head

April 12, 2018

Bladder EpiCheck Multi-Center Study Results Were Presented During the European Association of Urology (EAU) Annual Meeting

Clinical results of multi-center study with five leading urology centers were accepted as a poster and presented during the EAU meeting in Copenhagen, Denmark. The EAU meeting is the largest urology meeting in Europe and 2nd largest in the world.

read more >

Press Release
news head

April 5, 2018

Leading European Bladder Cancer Experts: The Bladder EpiCheck Urine Test Can Reduce Invasive Procedures

read more >

Article
news head

November 20, 2017

Nucleix Exhibited Bladder EpiCheck at the Annual Meeting of the European Multidisciplinary Meeting on Urological Cancers (EMUC)

Nucleix exhibited Bladder EpiCheck, best-in-class bladder cancer monitoring test, during the European Multidisciplinary Meeting on Urological Cancers (EMUC). The EMUC meeting one of Europe’s well-attended international conferences for multidisciplinary specialists with expertise in urological malignancies. During the meeting, Nucleix met

read more >

Article
news head

October 23, 2017

Nucleix Exhibited Bladder EpiCheck at the Annual Meeting of the Société Internationale d’Urologie (SIU) in Lisbon

Nucleix exhibited Bladder EpiCheck, best-in-class bladder cancer monitoring test, during the annual meeting of the Société Internationale d’Urologie (SIU). The SIU meeting is the world’s 3rd largest urology meeting that took place in Lisbon and included over 2,000 participants from

read more >

Press Release
news head

April 9, 2017

CE Mark Granted to Nucleix’s Bladder EpiCheck – Announcing Superior Results Over All Other Non-Invasive Tests in a European Multi-Center Study for Bladder Cancer Monitoring

The company will present its new results during the European Association of Urology (EAU) annual meeting in London (March 24th – 28th)   Rehovot, Israel, March 22nd 2017 – Nucleix, an innovative cancer detection and screening company, announced today that

read more >

Press Release
news head

March 16, 2017

Nucleix Will Exhibit Bladder EpiCheck at the 2017 EAU (European Association of Urology) Annual Meeting in London

Nucleix will announce new clinical results and latest developments in their booth   Rehovot, Israel, March 16th 2017 – Nucleix, an innovative cancer detection and screening company, announced today that it will exhibit its Bladder EpiCheck in the next annual

read more >

Press Release
news head

October 5, 2016

Nucleix Granted US Patent

Nucleix was granted a new patent for “Methods for distinguishing between Natural and Artificial DNA Samples”, under US patent number 9458503

read more >

Article
news head

June 20, 2016

A new noninvasive monitoring test for bladder cancer

Nucleix is making a simple urine test to monitor the disease, which has the highest lifetime treatment cost per patient of all types of cancer.

read more >